EVENTS DURING THE SECOND QUARTER
- Preclinical data with tasquinimod in myelodysplastic neoplasms published in HemaSphere (April 14)
- Active Biotech publishes results from the LION study on ocular absorption and distribution of laquinimod in the eye (April 20)
- Active Biotech announced that European regulatory approval has been obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech, Oncode and HOVON (May 13)
EVENTS AFTER THE END OF THE PERIOD
- First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis (July 24)
- Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis (August 18)
FINANCIAL SUMMARY
| SEK M | Apr-Jun | Jan-Jun | Full-year |
| 2026 2025 | 2026 2025 | 2025 |
| Net sales |
| - |
| - | - |
| Operating profit/loss | -10.2 | -11.3 | -18.8 | -22.5 | -37,6 |
| Profit/loss after tax | -10.1 | -11.2 | -18.4 | -22.2 | -37,3 |
| Earnings per share (SEK) | -0.38 | -0.91 | -0.70 | -1.81 | -2,77 |
| Cash and cash equivalents (at close of period) |
|
| 43.9 | 16.8 | 65,1 |
The report is also available at www.activebiotech.com
Active Biotech AB (Corp. reg. no. 556223-9227) / Scheelevägen 22, SE-223 63 Lund / +46 46 19 20 00